CTOs on the Move

HumanTouch

www.humantouch.com

 
Human Touch is the leading provider of high-quality, innovative lifestyle products, massage chairs, and experiences that deliver life-changing benefits. We have been making people feel better for over 35 years by developing state-of-the-art massage products containing patented massage systems that replicate techniques used by massage professionals. Our wellness solutions help to reduce muscle tension and pain caused by today`s hectic lifestyle so that people can do what they do - better. Combining advanced technology and attractive design, Human Touch innovations are perfectly suited for today`s modern and traditional living spaces. Our customers include serious athletes looking to recover from intensive ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Les Buday
 Director of Cybersecurity Profile

Similar Companies

Rimidi

What if one solution could change everything you thought you knew about Diabetes?

CircuLite

CircuLite is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Hackensack, NJ. To find more information about CircuLite, please visit www.circulite.net

Eclipse Salon

Eclipse Salon is a Cortez, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Innovative Neurotronics

Innovative Neurotronics, Inc. is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dimension Therapeutics

Dimension Therapeutics, Inc. is a rare disease company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced adeno-associated virus (AAV) delivery technology. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from OTC deficiency and GSDIa; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in hemophilia B, which is expected to enter clinical testing in the second half of 2015. Dimension has preferred access to multiple AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases.